- AU$125.58m
- AU$113.30m
- AU$27.57m
- 56
- 36
- 40
- 42
Annual cashflow statement for Cyclopharm, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.158 | 0.396 | 0.45 | 1.29 | 1.4 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -8.93 | -1.63 | -6.66 | -7.2 | -12.6 |
| Capital Expenditures | -0.531 | -1.16 | -1.55 | -0.538 | -0.972 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.343 | 0 | — | 0.03 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -0.874 | -1.16 | -1.55 | -0.508 | -0.972 |
| Financing Cash Flow Items | 0.056 | -1.66 | 0.446 | 0.142 | -1.14 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.986 | 30.2 | -0.726 | -1.02 | 22.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.8 | 27.4 | -8.95 | -8.57 | 8.84 |